Wall Street analysts expect MannKind Co. (NASDAQ:MNKD – Get Rating) to post $16.33 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for MannKind’s earnings, with the highest sales estimate coming in at $16.60 million and the lowest estimate coming in at $16.00 million. MannKind posted sales of […]
MannKind Co. (NASDAQ:MNKD – Get Rating) – Stock analysts at Cantor Fitzgerald issued their FY2023 earnings per share estimates for MannKind in a report issued on Monday, June 6th. Cantor Fitzgerald analyst B. Folkes expects that the biopharmaceutical company will earn ($0.24) per share for the year. A number of other equities research analysts also […]
MannKind (NASDAQ:MNKD – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as […]
National Bank of Canada FI acquired a new stake in shares of MannKind Co. (NASDAQ:MNKD – Get Rating) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 23,270 shares of the biopharmaceutical company’s stock, valued at approximately $101,000. Several other institutional investors also recently bought and sold shares of MNKD. Emerald Advisers LLC raised […]
Equities analysts expect MannKind Co. (NASDAQ:MNKD – Get Rating) to announce sales of $10.44 million for the current fiscal quarter, according to Zacks. Three analysts have made estimates for MannKind’s earnings, with the lowest sales estimate coming in at $10.10 million and the highest estimate coming in at $10.70 million. MannKind reported sales of $17.44 […]